MANGOCEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
MGRX$0.19-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income
** Consolidated Statements of Operations**
| For The Year | For The Year | |
|---|---|---|
| Ended | Ended | |
| December 31, 2024 | December 31, 2023 | |
| Revenues | ||
| Revenues | $615,873 | $731,493 |
| Cost of revenues | 93,296 | 154,900 |
| Cost of revenues - related party | 142,613 | 145,092 |
| Gross profit | 379,964 | 431,501 |
| Operating expenses | ||
| General and administrative expenses | 3,000,571 | 3,319,417 |
| Salary and benefits | 1,063,781 | 977,890 |
| Advertising and marketing | 1,478,663 | 2,097,505 |
| Investor relations | 453,749 | 1,100,465 |
| Stock based compensation | 2,355,193 | 2,155,114 |
| Total operating expenses | 8,351,957 | 9,650,391 |
| Loss from operations | (7,971,993) | (9,218,890) |
| Other expense | ||
| Interest Expense | 13,700 | - |
| Imputed interest - related party | - | (6,473) |
| Amortization of intangible assets | 721,533 | - |
| Total other expense | 735,233 | (6,473) |
| Loss before income taxes | (8,707,226) | (9,212,417) |
| Income taxes | - | - |
| Net loss | (8,707,226) | (9,212,417) |
| Net loss attributed to non-controlling interest | (1,081) | - |
| Net loss attributed to Mangoceuticals, Inc. | (8,706,145) | (9,212,417) |
| Basic and diluted loss per share | ||
| Basic and diluted loss per share | $(4.84) | $(8.58) |
| Weighted average number of shares outstanding | ||
| Basic and diluted* | 1,978,966 | 1,074,202 |
| * | Shares and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 15 reverse stock split. |
|---|
Mangoceuticals, Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
| For The | For The | |
|---|---|---|
| Year Ended | Year Ended | |
| December 31, 2024 | December 31, 2023 | |
| Net loss attributable to Mangoceuticals, Inc. | $(8,707,226) | $(9,212,417) |
| Other comprehensive expense | ||
| Foreign currency adjustments | (9,845) | - |
| Comprehensive loss | (8,717,071) | (9,212,417) |
| Other comprehensive expense | ||
| Net loss attributed to non-controlling interest | (1,081) | - |
| Comprehensive loss attributable to Mangoceuticals, Inc. | $(8,715,990) | $(9,212,417) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.